Qiagen N.V.

QGEN

NL0015001WM6

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:19:48 2024-05-13 am EDT			5-day change	1st Jan Change
44.14 ^USD	+1.22%		+3.64%	-1.44%

10:36am	Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test	MT
08:55am	Qiagen Obtains US FDA Clearance for Respiratory Syndromic Testing Panel	MT

QIAGEN NV : Warburg Research gives a Neutral rating

July 13, 2021 at 05:05 am EDT

Initially Neutral on the company, Warburg Research's analyst Ulrich Huwald maintained his recommendation. The target price is unchanged at EUR 46.20.

Latest news about Qiagen N.V.

Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test	04:36am	MT
Qiagen Obtains US FDA Clearance for Respiratory Syndromic Testing Panel	02:55am	MT
Qiagen, US FBI to Jointly Develop Digital PCR Assay for Forensics	May. 08	MT
QIAGEN Partners with FBI to Develop Digital PCR Assay for QIAcuity for Use in Forensics	May. 07	CI
QIAGEN Announces the Availability of QCI Secondary Analysis	May. 02	CI
QIAGEN NV : Berenberg reaffirms its Buy rating	Apr. 30	ZD
QIAGEN : A decent start to 2024; guidance unchanged	Apr. 30
QIAGEN NV : Deutsche Bank reiterates its Buy rating	Apr. 30	ZD
Qiagen Seeks Acquisitions	Apr. 30	CI
Transcript : Qiagen N.V., Q1 2024 Earnings Call, Apr 30, 2024	Apr. 30
QIAGEN NV : Jefferies remains Neutral	Apr. 30	ZD
QIAGEN NV : UBS remains Neutral	Apr. 30	ZD
QIAGEN NV : UBS remains Neutral	Apr. 30	ZD
QIAGEN NV : UBS sticks Neutral	Apr. 30	ZD
Qiagen Q1 Adjusted Earnings, Sales Decline; Q2 Outlook Issued, 2024 Guidance Affirms -- Shares Fall After Hours	Apr. 29	MT
Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024	Apr. 29	CI
Qiagen N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 28	CI
QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use	Apr. 24	CI
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
QIAGEN NV : Deutsche Bank reiterates its Buy rating	Apr. 16	ZD
Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024	Apr. 03	CI
Mybio Are the New Exclusive Partner for Qiagen in Ireland & Northern Ireland	Mar. 27	CI
QIAGEN Introduces QIAstat-Dx Analyzer 2.0 with Remote Test Results Access, Enhancing Collaboration Across Healthcare System	Mar. 25	CI
Qiagen Teams Up With Physicians Association for Tuberculosis Screening Program	Mar. 18	MT
Transcript : Qiagen N.V. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM	Mar. 05

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Berenberg MDx Day

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 09:32 am EDT

More Strategies

Ratings for Qiagen N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

43.61 USD

Average target price

50.19 USD

Spread / Average Target

+15.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QIAGEN N.V.	-1.44%	9.67B
MODERNA, INC.	+22.82%	44.96B
IQVIA HOLDINGS INC.	+1.09%	42.65B
LONZA GROUP AG	+45.89%	41.85B
CELLTRION, INC.	-5.31%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.14%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.29%	19.03B
BIO-TECHNE CORPORATION	+6.51%	12.75B
MEDPACE HOLDINGS, INC.	+28.65%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.98%	11.75B

Other Biotechnology & Medical Research

Qiagen N.V.

Equities

QGEN

NL0015001WM6

Biotechnology & Medical Research

QIAGEN NV : Warburg Research gives a Neutral rating

Latest news about Qiagen N.V.

Chart Qiagen N.V.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Qiagen N.V.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research